Prevalence, prescription patterns, and quality of life of anaemia in adults with chronic renal disease

dc.contributor.authorSandeep, Akkam
dc.contributor.authorElumalai, Karthikeyan
dc.contributor.authorWilliams, Helen
dc.contributor.authorSalkapuram, Sunilkumar
dc.contributor.authorAnandakumar, Shanmugam
dc.contributor.authorSrinivasan, Sivaneswari
dc.date.accessioned2023-12-29T19:16:10Z
dc.date.available2023-12-29T19:16:10Z
dc.date.issued2023-12
dc.descriptionThe Raghavendra Institute of Pharmaceutical Education and Research Institution Review Board gave its approval for this study, and it also obtained data usage permission. The study period was November 2022 to April 2023 (date of approval: October 22, 2022, RIPER/IRB/2022/045).
dc.description.abstractIntroduction and aim. Anaemia is a chronic kidney disease (CKD) condition characterised by a decline in glomerular filtration rate (GFR) and impaired kidney function. The aim of this study was to assess the prevalence, prescribing patterns, and quality of life of anaemia in patients with chronic renal disease who were adults (>18 years of age) at a tertiary care hospital. Material and methods. Data on demographic characteristics, laboratory results, medication prescriptions, and quality of life assessments were collected. Statistical tests were performed to determine associations between anaemia prevalence and factors like age, gender, and CKD stage. The study included 132 patients, with a gender distribution of 89 men and 43 women. Results. The most frequently prescribed drugs are epoetin (15.06%), multivitamins (14.82%), iron (10.65%), folic acid (10.22%), calcium carbonate (8.17%), calcitriol (5.6%), and omeprazole (4.22%). The cardiovascular system, blood disorders, and blood-producing organs come after the gastrointestinal tract and metabolism in the first anatomical level of the ATC classification. Conclusion. It suggests hospital audits and recommendations for improved prescription practices. Further investigation into anaemia causes and drug class appropriateness is needed, and implementing improvements could potentially improve health outcomes.eng
dc.description.sponsorshipThe author, Dr. Shanmugam Anandakumar, would like to thank the Indian Council of Medical Research (ICMR) for his ICMR Research Associate (RA) Scheme (Project ID: 2021: 9012; No: BMI/11(16)/2022).
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 21, z. 4 (2023), s. 785–792
dc.identifier.doi10.15584/ejcem.2023.4.20
dc.identifier.eissn2544-1361
dc.identifier.urihttps://repozytorium.ur.edu.pl/handle/item/9509
dc.language.isoeng
dc.publisherPublishing Office of the University of Rzeszow
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Poland*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/pl/*
dc.subjectanaemia
dc.subjectchronic kidney disease
dc.subjectprescribing pattern
dc.subjectquality of life
dc.titlePrevalence, prescription patterns, and quality of life of anaemia in adults with chronic renal disease
dc.typearticle

Pliki

Oryginalny pakiet

Aktualnie wyświetlane 1 - 1 z 1
Ładowanie...
Obrazek miniatury
Nazwa:
16.prevalence_prescription_patterns_and_quality_of_life_of_anaemia.pdf
Rozmiar:
201.74 KB
Format:
Adobe Portable Document Format

Pakiet licencji

Aktualnie wyświetlane 1 - 1 z 1
Nazwa:
license.txt
Rozmiar:
1.28 KB
Format:
Item-specific license agreed upon to submission
Opis: